Ownership and insider activity for Elanco Animal Health Incorporated (ELAN): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate.
Price
| Price | $24.10 (closing price, November 2, 2026) |
| Market Cap | $12.0B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-16 | Modi Rajeev A. | A-Award | 62 | |
| 2026-10-16 | Simmons Jeffrey N | A-Award | 120 | |
| 2026-10-16 | VanHimbergen Robert M | A-Award | 8 | |
| 2026-10-15 | Bettington Timothy J | S-Sale | 4,350 | $100K |
| 2026-10-02 | Modi Rajeev A. | A-Award | 66 | |
| 2026-10-02 | Simmons Jeffrey N | A-Award | 127 | |
| 2026-10-02 | VanHimbergen Robert M | A-Award | 8 | |
| 2026-09-30 | Anand Kapila K | A-Award | 642 | |
| 2026-09-18 | Simmons Jeffrey N | A-Award | 126 | |
| 2026-09-18 | Modi Rajeev A. | A-Award | 65 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258.8M | $323.4M | $474.8M | $334.0M | $495.0M | $638.0M | $345.0M | $352.0M | $468.0M | $545.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $630.7M | $601.9M | $709.4M | $889.9M | $1.08B | $1.03B | $1.00B | $1.01B | $886.0M | $940.0M |
| Inventory | $875.6M | $1.06B | $1.00B | $1.05B | $1.58B | $1.37B | $1.54B | $1.74B | $1.57B | $1.74B |
| Total Current Assets | $1.95B | $2.12B | $2.50B | $2.37B | $3.42B | $3.27B | $3.28B | $3.41B | $3.21B | $3.46B |
| Property, Plant & Equipment | $741.8M | $920.3M | $922.4M | $955.3M | $1.32B | $1.05B | $999.0M | $1.03B | $993.0M | $1.41B |
| Goodwill | $2.58B | $2.97B | $2.96B | $2.99B | $6.22B | $6.17B | $5.99B | $5.09B | $4.41B | $4.78B |
| Intangible Assets | $2.62B | $2.67B | $2.45B | $2.48B | $6.39B | $5.59B | $4.84B | $4.49B | $3.68B | $3.41B |
| Total Assets | $8.10B | $8.94B | $8.96B | $8.99B | $17.69B | $16.48B | $15.49B | $14.36B | $12.61B | $13.36B |
| Accounts Payable | $228.2M | $203.8M | $205.2M | $222.6M | $501.0M | $416.0M | $390.0M | $270.0M | $296.0M | $368.0M |
| Short-term Debt | 0 | 0 | $29.0M | $24.5M | $555.0M | $294.0M | $388.0M | $38.0M | $44.0M | $74.0M |
| Total Current Liabilities | $618.9M | $632.6M | $970.7M | $818.5M | $2.08B | $1.65B | $1.70B | $1.24B | $1.31B | $1.60B |
| Long-term Debt | 0 | 0 | $2.44B | $2.33B | $5.57B | $6.03B | $5.45B | $5.74B | $4.28B | $3.94B |
| Total Liabilities | $1.07B | $1.15B | $3.76B | $3.44B | $9.22B | $8.97B | $8.20B | $8.14B | $6.52B | $6.81B |
| Retained Earnings | 0 | 0 | $16.4M | $84.3M | -$477.0M | -$979.0M | -$1.06B | -$2.29B | -$1.95B | -$2.18B |
| Total Equity | $7.03B | $7.79B | $5.20B | $5.55B | $8.48B | $7.51B | $7.29B | $6.22B | $6.10B | $6.55B |
| Total Debt | 0 | 0 | $2.47B | $2.35B | $6.13B | $6.32B | $5.84B | $5.77B | $4.32B | $4.02B |
| Net Debt | -$258.8M | -$323.4M | $2.00B | $2.02B | $5.63B | $5.68B | $5.49B | $5.42B | $3.85B | $3.47B |
| Working Capital | $1.33B | $1.49B | $1.53B | $1.55B | $1.34B | $1.63B | $1.58B | $2.17B | $1.90B | $1.86B |
Financial Health
| Debt / Equity | 0.59 |
| Current Ratio | 2.05 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.34 |
Profitability
| Return on Equity | -3.02% |
| Return on Invested Capital | 3.92% |
| Return on Assets | -1.47% |
| Gross Margin | 52.59% |
| Operating Margin | 9.20% |
| Net Margin | -3.96% |
Related companies: MRK · IDXX · NEOG · ZTS
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ELAN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks